17,261 trials
Hepatitis C Virus
Primary: Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 2 — 83.3; 82.6; 62.5 percentage of…
Head and Neck Neoplasms
Primary: Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site — 76.7 percentage of participants
Prostate Cancer Metastatic
Primary: Progression Free Survival (PFS) Time — 3.3; 3.4; 4.3 months
Cancer Survivorship · Safety and Efficacy · Quality of Life
Primary: Retention Rates and Class Attendance — 91; 81; 79; 83 percentage of participants
Cervical Adenocarcinoma · Cervical Adenosquamous Cell Carcinoma · Cervical Small Cell Carcinoma
Primary: The Diagnostic Sensitivity of PET/CT for Detection of Lymph Node Metastasis in Abdomen — 50; 65 percentage of participants
Menopause · Vulvovaginal Atrophy · Painful Intercourse
Primary: Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells) — -54.4; -4.8 Percentage of Parabasal Cells — p=<0.0001
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Myelodysplasia
Primary: One-year Survival — 50 percentage of participants
Stem Cell Transplantation · Ventricular Dysfunction, Left
Primary: Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade…
Osteoarthritis Pain
Primary: Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing — 12.39; 2.43; 27.30; 3.74 mg
Smallpox
Primary: Geometric Mean Peak Plaque Reduction Neutralization Titer (PRNT) After Second Vaccination — 138.0; 55.1; 75.9; 103.5 titers
Juvenile Idiopathic Arthritis
Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…
Kidney Transplantation
Primary: Percentage of Participants With Biopsy-confirmed Acute Rejection (BCAR) at Month 6 Assessed by Local Review — 12.7; 26.3; 18.8; 16.7 percentage of participants
Epilepsy
Primary: Number of Participants With Treatment-emergent Non-serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs) — 112; 33 Participants
Asthma
Primary: Change From Baseline in Blood Eosinophil Levels at Week 12 (Day 84) — 0.43; 0.14; 0.12; 0.14 Proportion of Baseline blood eosinophil
Extensive-Stage Small Cell Lung Cancer
Primary: 1-year Survival — 38 percentage of participants